Prevention and treatment of amyloid-associated disorders
CA 2377382 A1 · Owner: Scios, Inc. · Inventors: Catalano, Rosanne; Higgins, Linda S.; Hyslop, Paul Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate .beta.-amyloid PGE2-mediated activation which can be identified by , cellular activity such as secretion of cytokines e.g. TNF-.alpha. and IL-, 1.alpha.. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound or , by …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.